Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR and ONLY ADVR -- Ignore unavailable to you. Want to Upgrade?

To: DAN LITTLE who wrote (37)	9/25/2000 12:27:44 PM
From: Richard Phillips	Read Replies (1) \| Respond to of 278

Hi Dan & ALL: Been busy with my research and don't post on RB anymore. Too many BS post on there. I hope that this board stays on the subject of ADVR. ------------------- Found this while looking at Ovarian Cancer items: clinicalstudies.info.nih.gov Title: Vaccine Therapy with Tumor Specific p53 Peptides in Adult Patients with Adenocarcinoma of the Ovary Number: 99-C-0137 Summary: This study will examine whether vaccination with a p53 peptide can boost an immune response to ovarian cancer and what the side effects are of the vaccine. **************************************************** Asked ADVR if this affected us in any way & the answer was: Thank you for your correspondence, however this does not impact our current research. Regards, --------------------------------------------------- Later guys: Pops ><>